Stay updated on EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page.

Latest updates to the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded a new revision entry 'Revision: v3.3.3' to the Record History. Removed the 'HHS Vulnerability Disclosure' footer link and the older revision 'Revision: v3.3.2' from the page.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedRecord History now lists Revision v3.3.2 and removes Revision v3.2.0.SummaryDifference0.1%

- Check37 days agoChange DetectedThe operating-status notice about government funding was removed from the page.SummaryDifference0.7%

- Check51 days agoChange DetectedThe screenshots show the Record History page for NCT02183870 with version entries from 2014 to 2022. The content and structure remain consistent, with only minor UI updates.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded a prominent operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference12%

- Check87 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.3%

Stay in the know with updates to EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page.